1. Scrip
  2. >>Therapy Areas
  3. >>Cardiovascular

After Two Jury Verdicts, Court Finds Repatha Patents Invalid

 
• By Brenda Sandburg

Delaware district court rules patent claims for antibodies targeting PCSK9 are invalid for lack of enablement; saga to continue with Amgen appeal.

Gavel on chess board with figures. Law chess concept, 3D rendering

Amgen Inc. was dealt a blow in its long battle with Sanofi/Regeneron Pharmaceuticals Inc. as a district court found that its Repatha (evolocumab) patents were invalid for lack of enablement. The decision means that, for now, Sanofi and Regeneron will continue to market their competing PCSK9 inhibitor Praluent (alirocumab) in the US without worrying about potential damages.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cardiovascular

More from Therapy Areas

Zai’s R&D Head Touts ‘Beauty’ Of Novel Internal Assets

 
• By Dexter Jie Yan

Two potentially first-in-class molecules signify Zai Lab’s renewed drive for the in-house discovery of drugs that it requires “to be innovative, differentiated and to have the potential to make a big difference for patients,” its global R&D head tells Scrip.

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.